Genomic Vision is a molecular diagnostics and technology company specialized in the development of single DNA detection tools for research and in vitro diagnostics
Florence Allouche, - President
PharmD - Paris University, MBA - HEC Paris , Board director certified - IFA/Sciences Po Paris. Biologist at AP-HP (Greater Paris Hospitals), she has several positions in diagnostics industry.
She created and ran for 16 years, the Tech Transfer Office of AP-HP. 1000 patent families filed, 300 license agreements signed, €25M of annual revenues, 75 startups created. Expert & mentor at the main Paris’s incubators, she represented French technology transfer at international level (AUTM, ASTP).
In 2016, Florence co-founded and was CEO of SPARINGVISION, a genomic medicines company, translating 20 years of world-leading ophthalmic research at the Paris’ Vision Institute, into vision saving treatments for retinitis pigmentosa, moving beyond single gene correction therapies to gene-independent treatments. SparingVision raised €60M and got several grants.
Florence is Professor at University Paris Cité, Faculty of Pharmacy, specialized in pharmaceutical innovation and entrepreneurship. Florence is founder and President of MYRPHARM ADVISORS, a consulting firm helping translational academic research by startup creation, tech transfer, business development, innovation management, funding, strategy, growth, and mentoring.(Member of the French National Academy of Pharmacy, Member of the Scientific Advisory Board of Venture Center of Excellence - EIT Health, Prev. Member of the Watching Committee for the Big Investment Plan under the authority of French Prime Minister (SGI), First Prize Biotech at the European Startups Competition CATAPULT 2019, Finalist of the Prix Galien International, New York (US) - Med’Startup, 2019, Mercure Entrepreneurs Award - HEC Paris 2019, Women Trajectory’s Award - HEC Paris 2018, Elected "Woman of the Year 2017” by the French financial magazine “La Tribune”)
Eric Edery - Vice-President
Eric J.Edery is a financial advisor and VC Fund partner.
Graduated in Finance from Sorbonne University, He has worked for 10y at Morgan Stanley Dean Witter in Paris on a Sovereign debt desk and an Equity sales department prior to joining the Private Wealth division in Zurich. Since 2016 he is advising Tech and Biotech companies accross Europe. He is on the advisory board of WebInfluence Group, Adtech company.
Mohammad Afshar - Member
Mohammad Afshar is the founder and CEO Ariana Pharma, a leading Artificial Intelligence (AI) drug development company based in Paris, FR, and Boston, USA. Ariana specializes in precisionmedicine clinical trials, translating multi-omic data into innovative clinical development plans and regulatory approvals.
Prior to Ariana, Mohammad was a founder and the Director of Drug Design at RiboTargets, Cambridge, UK. He set up and managed the platform which discovered and successfully licensed several novel therapeutic molecules. Before joining RiboTargets he held several academic positions including at the Department of Chemistry of the University of York, UK, and the CRBM of the CNRS in France. He holds a Medical Degree (DCEM), MPhil in Computer Science (DEA), a PhD in structural biochemistry and a Habilitation Doctorate (HDR) from the Faculty of Medicine of the University of Montpellier, France. Since 2014, he is on the investment advisory board of Seventure Partners VC fund.